Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).
Azarga has been studied in two main studies involving a total of 960 adults with open-angle glaucoma or ocular hypertension.
